The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 270 participants.
Also called NCT04654390
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 270 participants
- Registry
-
NCT04654390
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04654390. Randomized; double masking; primary purpose treatment. Start 2020-12-30 (actual); primary completion 2021-12-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- DWP16001 Amg
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct04654390- Content hash
b78a82cbd7b07907151e7df083fc2d6aa8503044b0672f33ba3f54ab105d772e